A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 756 participants.
Also called NCT07915609
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 756 participants
- Sponsor
- Registry
-
NCT07915609 -
2026-527180-15-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT07915609. Randomized; quadruple masking; primary purpose treatment. Start 2026-10-26 (actual); primary completion 2028-08-21 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)
- Condition
- Obesity
- Condition
- Overweight and/or Obesity
- Condition
- Knee Osteoarthritis
- Condition
- Diabetes Melliuts, Type 2
- Intervention (Drug)
- Berobenatide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Pfizer
Record details
- Record id
cardio:ct-nct07915609- Content hash
e5552cb957a2d54bb08f437f06dc0a880c339fda706998c6fae5386ecb156609